Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
VYNE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.31 - $4.30
Previous CloseN/A
Volume117.27K
Average Volume (3M)3.39M
Market Cap
$7.91M
Enterprise Value$30.93M
Total Cash (Recent Filing)$39.65M
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Nov 06, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding25,472,164
10 Day Avg. Volume1,721,200
30 Day Avg. Volume3,386,303
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.91
Enterprise Value/Revenue64.98
Enterprise Value/Gross Profit64.98
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$2.00Price Target Upside566.67% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Phase Ib Trial ResultsVyne has unblinded data from the Phase Ib PsO trial, showing a clear anti-inflammatory efficacy signal with all six patients showing PASI reduction.
Preclinical DataVYN202 has demonstrated promising preclinical data across multiple models of fibro-inflammatory disease and hematologic malignancies.
Regulatory ApprovalThe FDA lifted the clinical hold on 0.25 and 0.5mg doses of VYN202 for female patients, offering encouraging proof-of-concept for VYN202 and highlighting its potential across various autoimmune indications.
Bears Say
Analyst DowngradeAnalyst downgrades VYNE from Buy to NEUTRAL as they await additional updates from management.
High Discontinuation RatesThe overall discontinuation rates were high, with 30.7% of repibresib-treated patients discontinuing treatment before 24 weeks, which was higher than those seen in other approved or late-stage therapies.
Trial DiscontinuationThe Phase IIb study evaluating repibresib gel in nonsegmental vitiligo did not meet its primary or key secondary endpoint, leading to the termination of the extension phase of the trial.
VYNE Therapeutics News
VYNE FAQ
What was VYNE Therapeutics’s price range in the past 12 months?
VYNE Therapeutics lowest stock price was $0.30 and its highest was $4.30 in the past 12 months.
What is VYNE Therapeutics’s market cap?
VYNE Therapeutics’s market cap is $7.91M.
When is VYNE Therapeutics’s upcoming earnings report date?
VYNE Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.
How were VYNE Therapeutics’s earnings last quarter?
VYNE Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.093.
Is VYNE Therapeutics overvalued?
According to Wall Street analysts VYNE Therapeutics’s price is currently Undervalued.
Does VYNE Therapeutics pay dividends?
VYNE Therapeutics does not currently pay dividends.
What is VYNE Therapeutics’s EPS estimate?
VYNE Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does VYNE Therapeutics have?
VYNE Therapeutics has 25,472,164 shares outstanding.
What happened to VYNE Therapeutics’s price movement after its last earnings report?
VYNE Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of VYNE Therapeutics?
Currently, no hedge funds are holding shares in VYNE
VYNE Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (566.67% Upside)
$2.00 (566.67% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.59%
12-Months-Change
Fundamentals
Return on Equity
-67.73%
Trailing 12-Months
Asset Growth
-48.39%
Trailing 12-Months
Company Description
VYNE Therapeutics
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
VYNE Stock 12 Month Forecast
Average Price Target
$2.00
▲(566.67% Upside)
Technical Analysis
Ownership Overview
6.31% Insiders
3.56% Mutual Funds
22.28% Other Institutional Investors
65.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---